AbbottABT recently announced results for its AMPLATZER Amulet left atrial appendage (LAA) occlusion device in a bid to fortify its core Structural Heart business. Data was presented at EuroPCR, the ...
St. Jude Medical (STJ) received an FDA safety alert for its Amplatzer ASO, a minimally-invasive implantable cardiac device used to treat atrial septal defect. The problem? In one to three of every ...
The Food and Drug Administration clearance and CE mark position Abbott to sell its Amplatzer Piccolo Delivery System in the U ...
PARIS, France—Left atrial appendage (LAA) occlusion with the Amplatzer Amulet (Abbott) reduces the risk of ischemic stroke in real-world use through 2 years, for the most part without the need for ...
(UPDATED) Patent foramen ovale (PFO) closure using the Amplatzer device for the prevention of recurrent stroke should be approved as an option for patients with cryptogenic stroke, the majority of a ...
Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...
ABBOTT PARK, Ill., Aug. 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the Amulet™ LAA Occluder IDE trial, a multi-center, head-to-head study comparing the company ...
Medical devices major St. Jude Medical Inc. ( STJ) is voluntarily recalling its Amplatzer TorqVue FX Delivery System because the product could cause fatal injuries to patients. The Food and Drug ...
- Amulet is the first and only minimally invasive treatment option to offer immediate closure of the left atrial appendage (LAA), so blood-thinning medication isn't needed following implantation - The ...
Dublin, June 07, 2022 (GLOBE NEWSWIRE) -- The "Global PFO Amplatzer Market, By Type, Application & By Region - Forecast and Analysis 2022-2027" report has been added to ResearchAndMarkets.com's ...
Abbott ABT recently announced results for its AMPLATZER Amulet left atrial appendage (LAA) occlusion device in a bid to fortify its core Structural Heart business. Data was presented at EuroPCR, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback